Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy

Lung Cancer Clinical Trial

— ALMERA  

Official title:

A Phase II Study to Investigate a Combination of Metformin With Chemo-Radiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02115464
• Other study ID #: OCOG-2014-ALMERA
• Status: Terminated
• Phase: Phase 2
• Start date: December 17, 2014
• Est. completion date: April 21, 2020

Study information

• Verified date: April 2020
• Source: Ontario Clinical Oncology Group (OCOG)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ALMERA is a randomized, phase II, open label study in patients with locally advanced non-small cell lung cancer (NSCLC) which will compare standard radiotherapy plus concurrent chemotherapy with or without consolidation versus the same treatment plus concurrent Metformin continuing for 12 months. Metformin is a well tolerated and inexpensive drug that has the potential to improve cancer patient outcomes.

Description:

This is a randomized, phase II, open label study in patients with locally advanced NSCLC which will compare standard RT (60-63 Gy for 6 weeks) plus concurrent Cisplatin-based chemotherapy (CRT) with or without consolidation (standard arm) vs the same CRT with or without consolidation plus treatment with Metformin concurrent with CRT and continuing for a total of 12 months (experimental arm). Ninety-four eligible and consenting patients will be randomized to one of the two treatment arms. Patients randomized to the experimental arm will receive Metformin (2000 mg/day) for a period of 12 months. Patients will be continuously evaluated for toxicity, will be assessed weekly at clinic visits during concurrent CRT treatment with or without consolidation and at follow up clinic visits at 3, 6, 9 and 12 months (from the date of randomization). Disease progression will be evaluated every 3 months for up to 12 months. All patients will be followed for up to 24 months (2 years) for survival.

The primary objective of this study is to determine the effect of Metformin on the proportion of patients free of disease progression at 12 months after initiation of drug treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 54
• Est. completion date: April 21, 2020
• Est. primary completion date: March 9, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age >/=18 to </= 80 years of age.

2. Unresected and pathologically (histologic) proven Stage 3a or Stage 3b NSCLC of adenocarcinoma, squamous cell, large cell or mixed histology, diagnosed within three months of study randomization.

3. Non-metastatic disease staged by: CT-chest and upper abdomen, brain MRI or contrast-enhanced CT within 12 weeks and physical examination and whole body FDG-PET/CT scan within 8 weeks prior to study randomization.

Exclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status >2.

2. More than 10% weight loss in the past 3 months.

3. Diabetic patient or anyone currently taking Metformin, insulin or other anti-hyperglycemic therapy.

4. Pulmonary Function Test (PFTs) (within the last 12 weeks) with Forced Expiratory Volume (FEV)1 < 1.2 litres per second or less than 50% of predicted.

5. Complete Blood Count (CBC) and biochemical renal and liver function profiles that do not permit chemotherapy treatment (as per institutional standard of care).

6. Fasting blood sugar levels of >/= 7.0 mmol per litre (within the last 12 weeks).

7. Prior systemic chemotherapy for lung cancer.

8. Prior radiotherapy that would overlap with the planned treatment area.

9. Prior invasive malignancy within the past 3 years (except non-melanomatous skin cancer non-invasive carcinoma in-situ of the breast, oral cavity or cervix).

10. Known Acquired Immune Deficiency Syndrome (AIDS).

11. Patients with increased risk for lactic acidosis:

• severe congestive heart failure (NYHA: class III or IV),

• history of metabolic acidosis,

• alcoholic intake of > 3 drinks daily,

• severe liver disease,

• renal failure

12. Known hypersensitivity or allergy to Metformin.

13. Known pregnancy or lactating female patient.

14. Geographic inaccessibility for follow-up.

15. Inability to provide informed consent.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• Metformin plus Chemo-radiotherapy
Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.

Radiation:
• Chemo-radiotherapy
Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Juravinski Cancer Centre	Hamilton	Ontario
Canada	Cancer Centre of Southeastern Ontario at Kingston General Hospital	Kingston	Ontario
Canada	Grand River Regional Cancer Centre	Kitchener	Ontario
Canada	Montreal General Hospital - McGill	Montreal	Quebec
Canada	Walker Family Cancer Centre - Niagara Health System	St. Catharines	Ontario
Canada	CancerCare Manitoba	Winnipeg	Manitoba

Sponsors (2)

Lead Sponsor	Collaborator
Ontario Clinical Oncology Group (OCOG)	Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	Progression free survival illustrates loco-regional disease control and freedom from distant metastasis	12 months
Secondary	Overall survival	Overall survival will be defined from the date of randomization until the date of death due to any cause.	18-24 months
Secondary	Time to loco-regional progression	Time to loco-regional progression is defined from the date of randomization until the date of confirmed loco-regional progression	18-24 months
Secondary	Distant progression-free survival	Distant progression-free survival is defined from the date of randomization until the date of distant progression, or death due to any cause.	18-24 months
Secondary	Toxicities	The adverse event reporting period begins from the time of randomization and ends 30 days after the last treatment (concurrent chemo-radiotherapy plus or minus Metformin). Only adverse events assessed as Grade 3 or higher will be documented.	12 months plus 30 days